US EditionAt ESMO, AstraZeneca and Gilead Square Off in Triple-Negative Breast Cancer
4 Articles
4 Articles
In its ambition to redefine cancer care, AstraZeneca promotes new data from its diverse portfolio of products and research lines in a new edition of the European Society of Medical Oncology (ESMO) Congress. More than 95 summaries will highlight nine approved drugs and nine possible new drugs from the company, including two abstracts presented at a Presidential late-breaking Symposium and 26 oral presentations.
AstraZeneca and Gilead Present Trial Results for Datroway and Trodelvy in Triple-Negative Breast Cancer at ESMO Conference
AstraZeneca and Gilead presented positive trial results […] The post AstraZeneca and Gilead Present Trial Results for Datroway and Trodelvy in Triple-Negative Breast Cancer at ESMO Conference first appeared on GeneOnline News. The post AstraZeneca and Gilead Present Trial Results for Datroway and Trodelvy in Triple-Negative Breast Cancer at ESMO Conference appeared first on GeneOnline News.
Datroway, Trodelvy contest in triple negative breast cancer heats up
BERLIN – Results have been revealed for the much-anticipated showdown at this year’s ESMO congress between AstraZeneca and Daiichi Sankyo’s Datroway and Gilead’s Trodelvy. Although Datroway might have some edge, it seems that the two ...
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
